FDA Hands Fast-Pass Voucher for Bizarre Rare Kid Disease Drug
Published Date: 1/21/2026
Notice
Summary
The FDA just gave a special fast-track ticket called a Priority Review Voucher to UCB, Inc. for their rare pediatric disease drug KYGEVVI, approved in November 2025. This voucher helps speed up future drug reviews, saving time and potentially money for the company. It’s a big win for patients with thymidine kinase 2 deficiency and a boost for UCB’s innovation efforts.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
KYGEVVI Approved for TK2 Deficiency
KYGEVVI (doxecitine and doxribtimine) was approved November 3, 2025, to treat thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients whose symptoms began at age 12 years or younger. The approval covers both adult patients and pediatric-onset cases with symptom onset on or before 12 years.
Priority Review Voucher Issued to UCB
The FDA issued a Rare Pediatric Disease Priority Review Voucher to the sponsor of KYGEVVI (doxecitine and doxribtimine). KYGEVVI was approved November 3, 2025, and the voucher is now formally awarded under section 529 of the FD&C Act.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in